Business context and reporting period
This summary is based on Neoleukin Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2022. The request identifies Neurogene Inc., but the filing identifies the registrant as Neoleukin Therapeutics, Inc. (Nasdaq: NLTX); verify that this is the intended filing.
Neoleukin is a pre-revenue biopharmaceutical company developing immunotherapies using de novo protein design. Its lead candidate, NL-201, is in a Phase 1 trial for advanced solid tumors. No product has been approved for sale, and the company reports no product revenue.
Financial results and liquidity
| Metric | Three months ended June 30, 2022 | Three months ended June 30, 2021 | Six months ended June 30, 2022 | Six months ended June 30, 2021 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $11.0 million | $9.8 million | $21.7 million | $19.5 million |
| General and administrative expense | $4.9 million | $5.3 million | $9.6 million | $10.6 million |
| Total operating expenses | $15.9 million | $15.1 million | $31.2 million | $30.1 million |
| Net loss | $15.7 million | $15.1 million | $31.0 million | $30.1 million |
| Net loss per share, basic and diluted | $0.28 | $0.27 | $0.56 | $0.55 |
| Net cash used in operating activities | Not presented quarterly | Not presented quarterly | $25.4 million | $26.6 million |
At June 30, 2022, cash and cash equivalents were $77.5 million and short-term investments were $38.9 million, for approximately $116.5 million combined. Working capital was $109.2 million; accumulated deficit was $424.5 million. The company reported no conventional borrowings; reported liabilities were primarily operating and finance lease obligations totaling approximately $12.4 million. No meaningful operating margin is available because the company has no revenue.
Cash, cash equivalents, and restricted cash declined by $64.9 million in the first half. Investing cash use of $39.8 million primarily reflected purchases of U.S. Treasury securities and property and equipment; operating cash use was $25.4 million. The Treasury securities had $72,000 of unrealized losses recorded in other comprehensive loss, with no year-to-date credit losses reported.
Material changes versus prior comparable periods
- Second-quarter R&D expense rose 12% year over year, primarily due to higher NL-201 clinical-trial costs. First-half R&D expense rose 11%.
- G&A expense declined 7% in the quarter and 9% for the first half, primarily due to lower personnel-related and facility-related costs.
- Net loss increased by $0.6 million for the quarter and $1.0 million for the first half versus 2021.
- The company shifted $39.1 million into available-for-sale U.S. Treasury securities during the first half; these are classified as short-term investments.
Outlook, commentary, and key risks
- Management expected available cash, cash equivalents, and short-term investments to fund planned operations through 2023. This is a forward-looking estimate, not a guarantee; the company states it will need substantial additional capital and may seek equity, debt, collaborations, or other financing.
- NL-201 dose escalation continued in two schedules, with intermediate dose levels added and the anticipated timeline to determine a Phase 2 dose extended. The company anticipated disclosing interim data in 2023. A new trial arm combining NL-201 with pembrolizumab began dosing in May 2022; the Phase 1 study is planned to enroll up to 252 patients.
- A Phase 1 trial in hematological malignancies was planned, with enrollment timing dependent on safety and dosing information from the ongoing solid-tumor trial. The filing gives no formal financial guidance beyond the cash-runway estimate.
- Key risks include clinical failure or delay, potentially serious cytokine-related or novel-protein immune reactions, reliance on third-party manufacturers and trial operators, supply-chain and COVID-19 disruption, competition, intellectual-property uncertainty, and the possibility that financing is unavailable or dilutive.
- The company reported no legal proceedings expected by management to have a material adverse effect. Management concluded disclosure controls were effective at a reasonable assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm that the Neoleukin Therapeutics filing, rather than a Neurogene filing, is the intended subject.
- Track NL-201 safety, dose escalation, timing and contents of the anticipated 2023 interim data, and any impact on trial plans.
- Assess whether the stated runway through 2023 remains supportable given actual operating cash use, clinical spending, inflation, and other costs.
- Review potential financing needs, including use of the $40 million at-the-market facility, under which no shares had been sold through June 30, 2022.
- Reconcile reported common shares outstanding (42.6 million at quarter-end) with the 12.7 million pre-funded warrants and the weighted-average share count used for loss per share (55.2 million in Q2).